Page 79 - 2021_04-Haematologica-web

A new promising CAR.CD30 T-cell therapy for CD30+ lymphoma.
A
B
CD
EF
Figure 5. The CD4/CD8 CAR.CD30 T-cell ratio is modulated by both cytokines and CD30+ tumor cells. (A) Analysis of the proliferation of non-transduced (NT, left panels), 28.4.1BB.ζ (middle panels) or 28.OX40.ζ (right panels) T cells, unstimulated (green histograms), stimu- lated with interleukin (IL)2 cytokine (blue his- tograms), stimulated with CD30+ Karpas-299 cells (pink histograms) and stimulated with CD30– BV173 cells (red histograms). (B) Analysis of the proliferation of NT (left panels), 28.4.1BB.ζ (middle panels) or 28.OX40.ζ (right panels) T cells, unstimulated (green his- tograms), stimulated with IL7-IL15 cytokine (blue histograms), stimulated with CD30+ Karpas-299 cells (pink histograms) and stimu- lated with CD30– BV173 cells (red histograms). (C, D) Flow cytometric analysis of CD4+ and CD8+ CAR+ T-cell percentage evaluated during in vitro exposure to IL2 (28.4.1BB.ζ, dotted gray bars; 28.OX40.ζ, dotted black bars), or IL7-IL15 (28.4.1BB.ζ, gray bars; 28.OX40.ζ, black bars). (E, F) Flow cytometric analysis of CD4+ and CD8+ T-cell percentage in CAR.CD30 T cells evaluated during long-term “stressed” co-cul- ture for 28.4.1BB.ζ (gray bars) and 28.OX40.ζ (black bars). Data from seven healthy donors are expressed as average ± standard deviation.
haematologica | 2021; 106(4)
995